BioNTech doses first patient in herpes vaccine study

The following is an excerpt from Reuters.

BioNTech headquarters in An der Goldgrube street, Mainz

BioNtech has dosed the first patient with its BNT163 herpes vaccine candidate designed to prevent genital lesions as part of a first-in-human Phase 1 clinical research study, the German vaccine maker said on Wednesday.

The vaccine candidate is meant to prevent HSV-2, the herpes simplex virus that causes genital herpes, and potentially HSV-1, which causes oral herpes and can lead to genital herpes.

It is the first result of the research collaboration established in 2018 between the University of Pennsylvania and BioNtech aimed at developing novel mRNA vaccine candidates for the prevention and treatment of various infectious diseases.

The Mainz-based firm said in a separate news release that it is advancing two mRNA vaccine candidates for malaria and tuberculosis, which it expects to enter first-in-human trials in late 2022 or early 2023.

Link to article here.

Leave a Comment

Your email address will not be published. Required fields are marked *

2 thoughts on “BioNTech doses first patient in herpes vaccine study”

  1. how much do we know about the new technique presently referred to as mRNA, where are the publicly published research studies? how does mRNA work, what’s in the injection? do they come with a package insert and what does it say?

    1. Some of your questions may be answered by reading Dr. John Campbell. He is on YOU TUBE. He is patient with his talk and understandable for the lay person.

Scroll to Top